<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854890</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan FLGI</org_study_id>
    <nct_id>NCT03854890</nct_id>
  </id_info>
  <brief_title>Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy</brief_title>
  <official_title>Fluorescent Lymphography-Guided Lymphadenectomy Using Indocyanine Green During Laparoscopic Radical Resection Of Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the number of lymph nodes retrieved with or without
      the use of intraoperative fluorescence lymphography in laparoscopic radical resection of
      rectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total number of lymph nodes retrieved</measure>
    <time_frame>During the surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The positive number of lymph nodes retrieved</measure>
    <time_frame>During the surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of the operation to remove the lymph nodes</measure>
    <time_frame>During the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rate of indocyanine green-positive para-aortic lymph node</measure>
    <time_frame>During the surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphadenectomy without indocyanine green injection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Laparoscopic lymphadenectomy will be performed in a standard way.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphadenectomy with indocyanine green injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.</description>
    <arm_group_label>Lymphadenectomy with indocyanine green injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of rectal carcinoma.

          -  Without multiple primary cancer.

          -  Without receiving neoadjuvant chemoradiotherapy.

          -  Sufficient organ function.

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Younger than 18 years or older than 75 years

          -  Synchronous or metachronous malignancy within 5 years.

          -  Patients with Intestinal obstruction or perforation or bleeding who require emergency
             surgery.

          -  Patients with a history of pelvic irradiation.

          -  ASA (American Society of Anesthesiologists) grade IV or V.

          -  Women who are pregnant (confirmed by serum Î²-Human Chorionic Gonadotropin in women of
             reproductive age) or breast feeding.

          -  Severe mental illness.

          -  Patients with severe emphysema, interstitial pneumonia, or ischemic heart disease who
             can not tolerate surgery.

          -  Patients who received steroid therapy within one month.

          -  Patients or family members misunderstand the conditions and goals of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinxiang Li, MD,PhD</last_name>
    <phone>+8613761291659</phone>
    <email>lxx1149@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanlei Ma, MD,PhD</last_name>
    <phone>+8613122680635</phone>
    <email>yanleima@live.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>May 12, 2019</last_update_submitted>
  <last_update_submitted_qc>May 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>LI XIN-XIANG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

